HC Wainwright Has Bullish Forecast for Talphera Q3 Earnings

Talphera, Inc. (NASDAQ:TLPH) – HC Wainwright lifted their Q3 2026 earnings estimates for shares of Talphera in a research note issued on Thursday, August 13th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings of ($0.06) per share for the quarter, up from their prior forecast of ($0.07). HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Talphera’s current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Talphera’s Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.23) EPS, FY2027 earnings at ($0.27) EPS and FY2028 earnings at ($0.17) EPS.

Talphera (NASDAQ:TLPH) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.06).

Several other analysts have also recently weighed in on TLPH. Zacks Research raised Talphera to a “hold” rating in a report on Monday, June 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Talphera in a report on Friday, July 17th. Westpark Capital initiated coverage on shares of Talphera in a research report on Thursday, April 30th. They issued a “buy” rating and a $3.00 price objective on the stock. Finally, Wall Street Zen raised shares of Talphera to a “hold” rating in a research note on Saturday, August 8th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $3.00.

Talphera Stock Up 0.8%

Talphera stock opened at $1.21 on Monday. The stock has a market cap of $62.80 million, a price-to-earnings ratio of -4.48 and a beta of 0.69. The business has a 50-day simple moving average of $1.21 and a 200 day simple moving average of $0.96. Talphera has a 52 week low of $0.40 and a 52 week high of $1.57.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TLPH. Nantahala Capital Management LLC raised its position in Talphera by 75.3% during the third quarter. Nantahala Capital Management LLC now owns 3,492,519 shares of the company’s stock valued at $3,120,000 after purchasing an additional 1,500,000 shares in the last quarter. Empery Asset Management LP purchased a new position in shares of Talphera in the 4th quarter worth about $1,520,000. Cantor Fitzgerald L. P. purchased a new position in shares of Talphera in the 4th quarter worth about $658,000. Renaissance Technologies LLC increased its position in shares of Talphera by 412.6% during the 4th quarter. Renaissance Technologies LLC now owns 257,380 shares of the company’s stock valued at $293,000 after purchasing an additional 207,166 shares during the last quarter. Finally, AIGH Capital Management LLC increased its position in shares of Talphera by 4.6% during the 4th quarter. AIGH Capital Management LLC now owns 4,661,502 shares of the company’s stock valued at $5,314,000 after purchasing an additional 206,957 shares during the last quarter. 37.67% of the stock is currently owned by hedge funds and other institutional investors.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.